•
Jun 30, 2023

iRhythm Q2 2023 Earnings Report

Reported a strong second quarter with balanced growth across Zio XT and Zio AT, driven by increasing demand for Zio services.

Key Takeaways

iRhythm Technologies reported revenue of $124.1 million, a 21.6% increase compared to the second quarter of 2022. The company's gross margin improved to 69.5%.

Revenue of $124.1 million, a 21.6% increase compared to second quarter 2022

Gross margin of 69.5%, a 70-basis point improvement compared to second quarter 2022

Cash, cash equivalents and marketable securities of $164.7 million as of June 30, 2023

Zio granted high medical needs designation by Japanese Ministry of Health, Labour, and Welfare

Total Revenue
$124M
Previous year: $102M
+21.6%
EPS
-$0.61
Previous year: -$0.79
-22.8%
Gross Margin
69.5%
Previous year: 68.8%
+1.0%
Gross Profit
$86.2M
Previous year: $70.2M
+22.7%
Cash and Equivalents
$61.6M
Previous year: $101M
-39.2%
Total Assets
$429M
Previous year: $436M
-1.4%

iRhythm

iRhythm

Forward Guidance

iRhythm projects revenue for the full year 2023 to grow approximately 18% to 19% compared to prior year results, ranging from approximately $485 million to $490 million. Gross margin for the full year 2023 is expected to range from 69% to 70% and adjusted operating expenses are expected to range between $417 million and $427 million. Adjusted EBITDA margin for the full year 2023 is expected to range from approximately 0% to 0.5% of revenues.